Get the Stockscreener App
7.60
1.20%
0.09
Eupraxia Pharmaceuticals Inc stock is traded at $7.60, with a volume of 354.62K.
It is up +1.20% in the last 24 hours and down -6.40% over the past month.
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.
See More
Previous Close:
$7.51
Open:
$7.27
24h Volume:
354.62K
Relative Volume:
1.62
Market Cap:
$442.74M
Revenue:
-
Net Income/Loss:
$-38.61M
P/E Ratio:
-7.6636
EPS:
-0.9917
Net Cash Flow:
$-29.20M
1W Performance:
+1.33%
1M Performance:
-6.40%
6M Performance:
+27.52%
1Y Performance:
+89.04%
1-Day Range:
$7.25
$7.69
1-Week Range:
$7.175
$7.97
52-Week Range:
$2.6801
$9.32
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Name
Eupraxia Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
-
Compare EPRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
7.60 | 437.50M | 0 | -38.61M | -29.20M | -0.9917 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 116.36B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 77.96B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.36B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-24-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-26-25 | Initiated | H.C. Wainwright | Buy |
| Jun-16-25 | Initiated | Canaccord Genuity | Speculative Buy |
| Feb-21-25 | Initiated | Craig Hallum | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Latest News
You need to know this Canadian biotech stock, analyst says - Cantech Letter
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Announces Earnings Results, Misses Estimates By $0.21 EPS - MarketBeat
Lifesci Capital Has Negative Outlook of EPRX FY2026 Earnings - MarketBeat
What is HC Wainwright's Estimate for EPRX Q1 Earnings? - MarketBeat
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Rating Lowered by Zacks Research - MarketBeat
Profit Recap: Will Eupraxia Pharmaceuticals Inc stock hit new highs in YEAR2026 Market WrapUp & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Q2 Earnings Estimate for EPRX Issued By HC Wainwright - MarketBeat
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Given New $11.00 Price Target at HC Wainwright - Defense World
EPRX stock on retail radar after strong remission data in digestive disease trial - MSN
Buyout Rumor: Whats BioXcel Therapeutics Incs historical return2026 Trade Ideas & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis - Investing News Network
H.C. Wainwright cuts Eupraxia Pharmaceuticals price target on higher costs - Investing.com
Eupraxia Pharmaceuticals Inc. - Baystreet.ca
HC Wainwright Has Lowered Expectations for Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price - MarketBeat
EPRX Stock On Retail Radar After Strong Remission Data In Digestive Disease Trial - Asianet Newsable
A Little-Known Biotech Is Gaining Retail Buzz With Its Latest Trial Data - Stocktwits
Eupraxia Pharmaceuticals Posts Strong Six-Month EoE Data for EP-104GI as RESOLVE Trial Advances - TipRanks
New Eupraxia data: EoE patients keep symptom relief for 24 weeks - Stock Titan
Freedman lifts Eupraxia (EPRX) stake to 9% after 2026 share purchases - Stock Titan
Aug Reactions: Is Eupraxia Pharmaceuticals Inc affected by consumer sentiment2026 Reactions & Community Consensus Trade Signals - baoquankhu1.vn
Short Interest in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Rises By 19.4% - MarketBeat
Ally Bridge Group NY LLC Buys New Shares in Eupraxia Pharmaceuticals Inc. $EPRX - MarketBeat
(EPRX) Technical Data (EPRX:CA) - Stock Traders Daily
Cantor Fitzgerald Keeps Their Buy Rating on Eupraxia Pharmaceuticals (EPRX) - The Globe and Mail
Eupraxia Pharmaceuticals (NASDAQ: EPRX) files 2025 Form 40-F with audited statements - Stock Titan
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results - Sahm
Eupraxia Widens Q4 Loss but Extends Cash Runway With $63 Million Financing - TipRanks
Eupraxia testing EoE drug extends cash runway to 2028 - Stock Titan
How the (EPRX.WT.A) price action is used to our Advantage - Stock Traders Daily
(EPRX) Market Insights and Trading Signals (EPRX:CA) - Stock Traders Daily
Canadian Investment Regulatory Organization Trading HaltEPRX.WT - marketscreener.com
Eupraxia Pharmaceuticals stock rating reiterated at Raymond James By Investing.com - Investing.com Canada
(EPRX) Stock Analysis and Trading Signals (EPRX:CA) - Stock Traders Daily
(EPRX.WT.A) Optimized Trading Opportunities - Stock Traders Daily
Eupraxia Pharmaceuticals Raises US$63.2 Million in February 2026 Equity Offering to Advance GI Pipeline - TipRanks
Eupraxia (EPRX) raises $63.2M to fund EP-104GI and GI pipeline - Stock Titan
Aug Patterns: Whats the beta of Eupraxia Pharmaceuticals Inc stockGDP Growth & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
(EPRX.WT.A) Trading Strategy and Analysis - Stock Traders Daily
Eupraxia Pharmaceuticals Closes US$63.2 Million Public Offering - Global Legal Chronicle
(EPRX.WT.A) Equity Market Report - Stock Traders Daily
(EPRX) Investment Performance Report (EPRX:CA) - Stock Traders Daily
(EPRX.WT.A) Trading Report (EPRX.WT.A:CA) - Stock Traders Daily
(EPRX) Proactive Strategies (EPRX:CA) - Stock Traders Daily
Bloom Burton initiates Eupraxia stock with buy rating on EoE drug - Investing.com Nigeria
Bloom Burton initiates Eupraxia stock with buy rating on EoE drug By Investing.com - Investing.com Australia
(EPRX.WT.A) Technical Pivots with Risk Controls - Stock Traders Daily
EPRXEupraxia Pharmac Latest Stock News & Market Updates - Stock Titan
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Downgraded to “Sell” Rating by Wall Street Zen - Defense World
Eupraxia Pharmaceuticals closes $63.2M public offering - Investing.com India
Eupraxia Pharmaceuticals Inc Stock (EPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.20%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):